Acurx Pharmaceuticals, Inc.
ACXP
$0.335
$0.0051.52%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.70M | 9.91M | 10.06M | 9.47M | 8.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.10M | 16.44M | 16.73M | 16.05M | 14.58M |
| Operating Income | -14.10M | -16.44M | -16.73M | -16.05M | -14.58M |
| Income Before Tax | -14.10M | -16.44M | -16.73M | -16.05M | -14.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.10 | -16.44 | -16.73 | -16.05 | -14.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.10M | -16.44M | -16.73M | -16.05M | -14.58M |
| EBIT | -14.10M | -16.44M | -16.73M | -16.05M | -14.58M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.88 | -1.09 | -1.15 | -1.17 | -1.14 |
| Normalized Basic EPS | -0.55 | -0.68 | -0.72 | -0.73 | -0.71 |
| EPS Diluted | -0.88 | -1.09 | -1.15 | -1.17 | -1.14 |
| Normalized Diluted EPS | -0.55 | -0.68 | -0.72 | -0.73 | -0.71 |
| Average Basic Shares Outstanding | 64.59M | 61.50M | 58.14M | 54.50M | 50.67M |
| Average Diluted Shares Outstanding | 64.59M | 61.50M | 58.14M | 54.50M | 50.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
